Biotech

All Articles

Analysts explore Avidity's DMD win, exposing nuances in records

.Avidity Biosciences pleased financiers with phase 1/2 records in Duchenne muscle dystrophy (DMD) Fr...

Actinogen's cortisol blocker neglects phase 2 anxiety research

.Actinogen Medical's cortisol blocker has actually skipped the primary endpoint of a phase 2 researc...

Bivictrix determines going exclusive only method to take ADC in to center

.Antibody-drug conjugates (ADCs) have actually been at the center of many a billion-dollar biobuck l...

TPG leadings up funds to $580M for financial investments around lifestyle sciences

.Property manager TPG, which has sustained biotechs like Sionna Therapeutics as well as Santa Clam A...

Merck ceases period 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT course has suffered another misfortune. Months after shuttering a stage 3 ca...

After a hard year, Exscientia folds in to Recursion

.After a year specified by pipeline cuts, the departure of its own chief executive officer as well a...

Cullinan, after $25M package, hands back bispecific to Port

.Cullinan Therapy was excited enough along with Harbour BioMed's bispecific immune system reactor th...

A closer look at Intense Biotech's Fierce 15

.In this particular full week's incident of "The Leading Pipe," our team're diving right into Fierce...

Lilly faces phase 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's party celebrating the approval of Alzheimer's condit...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial management hirings, firings ...